首页 社会内容详情
Sanofi ends cancer drug trials

Sanofi ends cancer drug trials

分类:社会

网址:

SEO查询: 爱站网 站长工具

点击直达

ETH单双博彩www.eth108.vip)采用以太坊区块链高度哈希值作为统计数据,ETH单双博彩数据开源、公平、无任何作弊可能性。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠怎么注册用户www.hg108.vip)皇冠怎么注册用户?皇冠真会员、代理注册其实很简单。访问网址www.hg108.vip,点击注册,然后充值USDT(需要实现到欧易平台购买到USDT),充值成功后,页面会展示账号资料给您。hg108.vip是皇冠正网在线上开设使用USDT充值、USDT结算的直营平台,资金安全,匿名性高。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。
 当前暂无评论,快来抢沙发吧~

发布评论